Entry Point Capital, LLC Adma Biologics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 6,433 shares of ADMA stock, worth $126,537. This represents 0.11% of its overall portfolio holdings.
Number of Shares
6,433
Previous 4,740
35.72%
Holding current value
$126,537
Previous $31.3 Million
129.9%
% of portfolio
0.11%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding ADMA
# of Institutions
295Shares Held
180MCall Options Held
535KPut Options Held
21.2K-
Black Rock Inc. New York, NY18.6MShares$367 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$286 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA13.2MShares$259 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.93MShares$176 Million0.03% of portfolio
-
State Street Corp Boston, MA8.06MShares$159 Million0.0% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.86B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...